Sign in
WithdrawnEarly phase 1

The Bronchiolitis in Hospitalized Infants Study

Key facts

Who runs it
IDeA States Pediatric Clinical Trials Network
Where
Little Rock and Omaha, United StatesSee the 2 sites
Trial code
Status
Withdrawn
Phase
Early phase 1
Started
9 Oct 2023
Ended
14 Apr 2025
Type of study
Interventional
Treatments tested
  • Dexamethasone Oral
Record updated
14 September 2023
Why it stopped
The study was withdrawn with no participants enrolled due to the need for an IND from the FDA, which significantly expanded the scope of the study beyond what was originally anticipated for a pilot project within this network.

Who can take part

Age
0 months to 24 months
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Infants <24 months of age at time of enrollment
  • Admitted to the hospitalist service with a diagnosis of bronchiolitis
  • RSV and COVID-19 Negative
  • At least one of the following clinical criteria:; personal history of breathing problems; personal history of eczema; parental history of asthma
  • Parental ability to speak and read English or Spanish

Who cannot take part

  • Currently taking corticosteroids (inhaled or oral) or have taken corticosteroids within 7 days prior to hospitalization (per parental report and chart review)
  • Known underlying heart failure, hypertension, gastrointestinal bleeding, liver disease, thyroid disease (per parental report and chart review)
  • Preterm Infant (born at < 34 weeks' gestation)
  • Diagnosis of asthma
  • Admission to the intensive care unit (ICU) at time of enrollment
  • Participants (caregivers) who, in the view of the investigator, whom are unlikely able to comply with the protocol requirements

Where in United States

  • Arkansas Children's HospitalLittle Rock, United States
  • University of Nebraska Medical CenterOmaha, United States

About the trial

What the trial wants to find out

The goal of this clinical trial is to determine whether it is possible to identify, enroll, and deliver the study intervention (the corticosteroid dexamethasone) in hospitalized infants with bronchiolitis.

Read full original descriptionShow less

Participants in this study will be given two doses of dexamethasone within 72 hours of enrollment, followed by 30 days of safety monitoring.

Results of this feasibility pilot study may be used to inform the design of a future randomized controlled trial, whose results in turn could induce a paradigm shift in acute management of bronchiolitis.

The group in the trial

  • Dexamethasone AdministrationTreatment being tested

    Dexamethasone will be given orally to all consented participants. Two doses will be administered within 12-48 hours, with at least the 1st dose administered during the bronchiolitis hospitalization. If the participant is discharged before the 2nd dose, it will be administered at home.

    Treatment: Dexamethasone Oral

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Bronchiolitis in Hospitalized Infants (BroncHI) Study: A Feasibility Trial Aimed to Identify and Treat Hospitalized Infants With Bronchiolitis Most at Risk for Recurrent Wheezing and Asthma
Record updated
14 September 2023